| ARES |
Report |
After-tax FRE/share |
BEAT |
pred ~$0.870 vs. cons $0.859 |
LOW |
| ARES |
Report |
FPAUM |
IN-LINE |
pred ~$417.0B vs. cons $414.2B |
LOW |
| ARES |
Report |
Capital deployment |
BEAT |
pred ~$35.0B vs. cons $33.9B |
LOW |
| ARES |
Guide |
FRE-margin expansion (FY 2026) |
UNCHANGED |
guide at high end of 0-150 bps vs. cons UNVERIFIED |
LOW |
| ARES |
Guide |
European-style realized performance income (FY 2026) |
UNCHANGED |
guide ~$350M vs. cons UNVERIFIED |
LOW |
| ARES |
Guide |
Fundraising (FY 2026) |
UNCHANGED |
guide as good as/better than 2025 record vs. cons UNVERIFIED |
LOW |
| ARES |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.5% |
— |
LOW |
| ARES |
Return |
5-day cumulative residual |
-3.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — maintained forward targets outweigh a modest operating beat |
LOW |